Why the study?
Does dabigatran etexilate provide effective anticoagulation for the prevention of venous thromboembolic complications in patients with lower extremity long bone fractures compared to parenteral direct anticoagulants followed by vitamin K antagonists?
Does dabigatran etexilate provide effective anticoagulation for the prevention of venous thromboembolic complications in patients with lower extremity long bone fractures compared to parenteral direct anticoagulants followed by vitamin K antagonists?
Dabigatran etexilate provides effective and stable anticoagulation without the need for routine coagulation monitoring in patients with lower extremity long bone fractures.
Answers are grounded in this paper and cite their sources.
May support dabigatran without routine monitoring in fracture patients; leaves open randomized confirmation versus standard regimens.
Complex dynamic examination of 68 patients with fractures of lower extremities long bones. In first comparative group (36 patients, mean age 36.3±1.4 years) prevention of thromboembolic complications was performed with parenteral direct anticoagulants followed by vitamin K antagonists. In second group (32 patients, mean age 39.3±2.0 years) dabigatran etexilate was used. Duration of anticoagulant therapy made up 30 days. It was noted that in fractures of long bones of the extremities application of dabigatran etexilate ensured effective, prognosticating, stable anticoagulant action and did not require routine control of coagulation parameters that enabled to recommend that drug for wider use in trauma and orthopaedic patients.
No takes yet. Share an insight, caveat, or question.
А. М. Мироманов (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: